A validity inspection study of the treat-to-target strategy with golimumab for the treatment of rheumatoid arthritis patient

A validity inspection study of the treat-to-target strategy with golimumab for the treatment of rheumatoid arthritis patient - Go-Go trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009425

Enrollment

150

Registered

2012-12-01

Start date

2012-12-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

The dose of golimumab should be fixed as 50 mg/month for all period. Treat-to-target strategy might be achieved by MTX or other DMARDs for one year. The goal of treatment is low disease activity. Trea

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with active rheumatoid arthritis 2. Patients who will receive the treatment by golimumab 3. Patients who is receiving MTX (no matter on dose) 4. Over moderate disease activity score. DAS28>=3.2 5. Glucocorticoid use should be under 7.5 mg/day

Exclusion criteria

Exclusion criteria: 1. Patients who show the allergic reaction for golimumab 2. The use of previous biologics is not included in exclusion criteria

Design outcomes

Primary

Measure	Time frame
The rate of RRP (Radiographic rapid progression) at 6 and 12 months	—

Secondary

Measure	Time frame
1.The change of DAS28-ESR, DAS28-CRP, SDAI and remission rate based on these composite measures 2.The change of mTTS 3.The change of CRP, ESR, MMP-3 4.The change of HAQ score 5. Prevalence of adverse events	—

Countries

Japan

Contacts

Public ContactTatsuya Koike

Osaka City University Medical School Center for Senile Degenerative Disorders

tatsuya@med.osaka-cu.ac.jp06-6646-6010

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026